Clinical Trials Logo

Brain Metastases, Adult clinical trials

View clinical trials related to Brain Metastases, Adult.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05999357 Not yet recruiting - Clinical trials for Brain Metastases, Adult

JDQ443 for KRAS G12C NSCLC Brain Metastases

STRIDER
Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

The goal of this phase II clinical trial is to evaluate the intracranial efficacy of JDQ443, a KRAS G12C inhibitor in patients with KRAS G12C+ NSCLC and brain metastases (cohort A: asymptomatic, untreated brain metastases, cohort B: asymptomatic, treated brain metastases). The main question it aims to answer is to evaluate the intracranial efficacy, according to RANO-BM criteria, in patients with asymptomatic and untreated brain metastases. Participants will receive JDQ443 200 mg BID until unacceptable toxicity or disease progression.

NCT ID: NCT05620914 Not yet recruiting - Clinical trials for Brain Metastases, Adult

A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

PARAMETer
Start date: April 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine if the study drug, patritumab deruxtecan (HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab deruxtecan before surgery.

NCT ID: NCT04626206 Not yet recruiting - Clinical trials for Brain Metastases, Adult

Multi -paramEtric Imaging to Assess Treatment REsponse After Stereotactic Radiosurgery of Brain Metastases

METRE
Start date: December 2020
Phase:
Study type: Observational

After stereotactic radiosurgery (SRS) of brain metastases, patients undergo a standard brain magnetic resonance imaging (MRI) to assess treatment response 12 weeks after completion of treatment. The interpretation of this standard MRI can sometimes be challenging as it can be difficult to differentiate tumour getting bigger/returning (progression/recurrence) from expected radiotherapy treatment-related changes known as radionecrosis. This study is a pilot brain imaging study that is investigating if readily available forms of imaging such as contrast-clearance analysis MRI (also known as TRAMs) and/or 18 Fluoromethyl-choline positron emission tomography/computerised tomography (18F-choline PET/CT) are equivalent to multi-parametric MRI in their ability to differentiate tumour from radionecrosis. Multi-parametric MRI has the most evidence for its ability to discriminate tumour from radionecrosis but is resource intensive and not routinely available in most centres.